Personalized Medicine for Primary Treatment of Serous Ovarian Cancer
Author:
- Dan L. LongoDLDan L. Longo
- 19 December 2019
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 381 (25) , 2471-2474
Abstract
The introduction of “personalized medicine” has spurred major changes in oncology, but success has been spread unevenly across the spectrum of solid tumors. Although prognoses for adenocarcinoma of the lung and melanoma have been profoundly altered, other diseases, such as colon cancer and ovarian cancer, have lagged behind owing to differences in genetics and biology. One of the earliest classes of targeted therapies in ovarian cancer has been the PARP (poly[adenosine diphosphate–ribose] polymerase) inhibitors.1-3 In this issue of the Journal, investigators report the results of three randomized trials of three different PARP inhibitors for maintenance therapy in patients with ovarian . . .Keywords
This publication has 8 references indexed in Scilit:
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerNew England Journal of Medicine, 2019
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine, 2019
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerNew England Journal of Medicine, 2019
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialThe Lancet Oncology, 2019
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerClinical Cancer Research, 2016
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group studyGynecologic Oncology, 2015